Stereotaxis (NYSEAMERICAN:STXS) Shares Down 5.3% – Should You Sell?

Shares of Stereotaxis Inc. (NYSEAMERICAN:STXS) dropped 5.3% on Friday . The stock traded as low as $1.77 and last traded at $1.78. Approximately 590,981 shares traded hands during trading, an increase of 57% from the average daily volume of 375,655 shares. The stock had previously closed at $1.88.

Analyst Ratings Changes

STXS has been the subject of several recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of Stereotaxis in a research report on Wednesday. Piper Sandler reissued an “overweight” rating and set a $3.50 price target (down from $4.00) on shares of Stereotaxis in a research report on Wednesday, May 13th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $3.88.

Stereotaxis Price Performance

The firm has a 50-day moving average of $1.90 and a 200 day moving average of $2.14. The stock has a market capitalization of $173.98 million, a price-to-earnings ratio of -7.42 and a beta of 1.35.

Stereotaxis (NYSEAMERICAN:STXS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). Stereotaxis had a negative return on equity of 163.30% and a negative net margin of 69.50%.The firm had revenue of $8.64 million during the quarter, compared to analysts’ expectations of $9.24 million. On average, equities analysts forecast that Stereotaxis Inc. will post -0.2 earnings per share for the current year.

Institutional Trading of Stereotaxis

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in Stereotaxis by 106.5% in the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after buying an additional 5,910 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in Stereotaxis in the third quarter valued at approximately $38,000. WealthPLAN Partners LLC bought a new stake in Stereotaxis in the fourth quarter valued at approximately $29,000. Moneta Group Investment Advisors LLC bought a new stake in Stereotaxis in the third quarter valued at approximately $43,000. Finally, SG Americas Securities LLC bought a new stake in Stereotaxis in the fourth quarter valued at approximately $33,000. Institutional investors own 45.35% of the company’s stock.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.